ICM 203
Alternative Names: ICM-203; ICM-203-O; ICM-203-RLatest Information Update: 15 Jul 2022
At a glance
- Originator ICM
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Osteoarthritis
- Preclinical Rheumatoid arthritis
Most Recent Events
- 12 Jul 2022 ICM Biotech plans a phase I/II trial for Osteoarthritis in December 2022 (Intra-articular) (NCT05454566)
- 17 Mar 2022 Phase-I/II clinical trials in Osteoarthritis in Australia (Intra-articular) (NCT04875754)
- 13 May 2021 ICM Biotech Australia and ICM plans a phase I/II trial for Osteoarthritis (In adults, In the elderly) in Australia in June 2021 (NCT04875754)